Home › Trial NCT01393717
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
- Trial IDNCT01393717
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorCity of Hope Medical Center
- Enrollment57
- Start date2011-10-20
- ConditionsRecurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.